Tri Nguyen, MD
Cardiology · Phoenix, AZNPI 1255379442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 283 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Medtronic at 39.3% of the total. Reporting peaked in 2023 at $2,262 and has fallen 58.0% since, to $951 in 2025.
Across 283 payments — averaging $40.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abbott$2K
- Novartis$671
- Edwards Lifesciences$598
- Boston Scientific$573
- Abiomed$542
- plus $3K from 21 others
What the payments were for
- Travel & lodging$3753%
- Food & beverage$11,11497%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 36 | $4,523 |
| Abbott | 55 | $2,028 |
| Novartis | 29 | $671 |
| Edwards Lifesciences | 4 | $598 |
| Boston Scientific | 16 | $573 |
| Abiomed | 21 | $542 |
| Artivion, Inc. | 3 | $459 |
| Amgen | 24 | $414 |
| Arbor Pharmaceuticals, Inc. | 25 | $257 |
| E.r. Squibb & Sons, L.L.C. | 14 | $248 |
| AstraZeneca | 14 | $211 |
| Regeneron Healthcare Solutions, Inc. | 6 | $185 |
| Johnson & Johnson | 6 | $138 |
| Jazz Pharmaceuticals Inc. | 1 | $116 |
| Novo Nordisk | 5 | $108 |
| Pfizer | 5 | $89 |
| Philips North America LLC | 3 | $57 |
| Kestra Medical Technology Services, Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $42 |
| Impulse Dynamics (USA) Inc. | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $33 |
| Angiodynamics, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Biosense Webster, Inc. | 1 | $26 |
| GSK | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$2,029
- CoreValve Evolut$590
- CARDIOMEMS$467
- Edwards SAPIEN 3 Transcatheter Heart Valve$440
- 3F$432
- On-X$375
- RESOLUTE ONYX$356
- AZURE XT DR MRI SURESCAN$259
- JOT DX$183
- NA$175
- Reveal LINQ$175
- ATTESTA SR MRI SURESCAN$158
- HeartWare HVAD$149
- MitraClip$142
- AVVIGO Guidance System$133
- Impella$127
- PRALUENT$121
- SUNOSI$116
How this compares
Too few cardiology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 284 | $401,289 |
| XareltoRivaroxaban | 82 | $122,527 |
| Repatha SureclickEvolocumab | 129 | $104,773 |
| EntrestoSacubitril/Valsartan | 27 | $36,104 |
| BrilintaTicagrelor | 24 | $23,546 |
| JardianceEmpagliflozin | 17 | $22,548 |
| EdarbiAzilsartan Medoxomil | 24 | $15,768 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 18 | $11,411 |
| Flecainide Acetate | 151 | $10,581 |
| Praluent PenAlirocumab | 11 | $6,190 |
| Atorvastatin Calcium | 526 | $5,082 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 156 | $4,982 |
| Losartan Potassium | 419 | $4,809 |
| Midodrine Hcl | 32 | $4,377 |
| Potassium Chloride | 170 | $3,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $89 | $401,289284 claims |
| Johnson & JohnsonXarelto | $138 | $122,52782 claims |
| NovartisEntresto | $671 | $36,10427 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $257 | $27,17942 claims |
| AstraZenecaBrilinta | $211 | $23,54624 claims |
| Boehringer IngelheimJardiance | $42 | $22,54817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other cardiology in Phoenix
- Paul DuongPhoenix$11K
- Habteab FesehaYuma$18K
- Maher AwarYuma$5K
- Nitin PatelPrescott Valley$2K
- Douglas RothrockPrescott$156
- Frederick SimonieScottsdale$74
- Carolyn LarsenScottsdale$0
- Susan Wilansky MarkowitzScottsdale$0
- Gerald WolffTucson$0
- Abdul TajikScottsdale$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.